KCNAB3 encodes a regulatory beta subunit of voltage-gated potassium (Kv) channels that modulates channel inactivation and conducts ion transport 1. The protein increases inactivation of Kv1.5 alpha subunit-containing channels and may mediate potassium channel closure through NADPH-dependent mechanisms. KCNAB3 has emerged as a biomarker across multiple pathological conditions. In epilepsy, the H258R mutation accelerates potassium channel inactivation, inhibiting potassium current and increasing neuronal excitability, thereby promoting seizures 1. The gene serves as a highly informative age biomarker, showing strong correlation with chr17 age in children and adolescents aged 2-18 years through DNA methylation patterns 2. KCNAB3 methylation changes are also associated with oral pre-cancer progression and osteoarthritis, where it helps distinguish between immune-activated and immune-suppressed disease subtypes 34. Additionally, KCNAB3 variants have been linked to migraine pathogenesis, supporting the channelopathy hypothesis of migraine 5. The protein's involvement in immunomodulation is evidenced by its role in atherosclerosis prevention through monocyte function regulation 6. These findings establish KCNAB3 as a multifunctional regulatory protein with clinical significance across neurological, inflammatory, and age-related diseases.